Positive Response to One-Year Treatment With Burosumab in Pediatric Patients With X-Linked Hypophosphatemia

Frontiers in Pediatrics- Switzerland

doi 10.3389/fped.2020.00048

Full Text

Abstract

Available in

Categories

Date

February 18, 2020

Authors

Silvia Martín Ramos

Marta Gil-Calvo

Virginia Roldán

Ana Castellano Martínez

Fernando Santos

Publisher

Frontiers Media SA

Related search

Burosumab: At Long Last, an Effective Treatment for FGF23-Associated Hypophosphatemia

Journal of Bone and Mineral Research

Sports Medicine

English

X-Linked Hypophosphatemia: New Horizons

Clinical Pediatric Endocrinology

English

One-Year Metreleptin Improves Insulin Secretion in Patients With Diabetes Linked to Genetic Lipodystrophic Syndromes

Diabetes, Obesity and Metabolism

Internal Medicine

English

Hypertension Is a Characteristic Complication of X-Linked Hypophosphatemia

Endocrine Journal

English

HLA-Cw6-positive Patients With Psoriasis Show Improved Response to Methotrexate Treatment

Clinical and Experimental Dermatology

English

Antinuclear Antibodies Are Common and Linked to Poor Response to Omalizumab Treatment in Patients With CSU

Allergy: European Journal of Allergy and Clinical Immunology

English

One-Year Treatment Continuation in Patients Switched to Paliperidone Palmitate

Journal of Clinical Psychiatry

English

Aberrant Phex Function in Osteoblasts and Osteocytes Alone Underlies Murine X-Linked Hypophosphatemia

Journal of Clinical Investigation

English

One-Year Mortality in Patients With Community-Acquired Pneumonia

Journal of Respiratory Infections

English